Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Is death an adverse event aka side effect of multiple myeloma? I’ll admit that the study linked below may be difficult for multiple myeloma (MM) patients to read. Learning about how end-stage multiple myeloma patients die may be rough. I felt a bit overwhelmed myself when I first came upon the study. Once I got into it however, I realized that the info contained in the study might actually help newly diagnosed MM patients understand their cancer and pursue appropriate lifestyle therapies.
First and foremost, newly diagnosed MM patients should understand that almost a third of patients die before or during their first line of therapy.
I have to conclude that this is because MM is often diagnosed late. A late MM diagnosis can mean extensive bone or kidney damage or a serious infection has occured and the patient has few therapy options.
Secondly, the study points out that response to conventional therapies is highly “variable.” This means that some MM patients enjoy 10 year remissions while some patients relapse during their first year of remission.
Lastly, the study glibly states that “most deaths at later lines where due to progressive disease.” While this statement is vague, I have to conclude that once MM patients have become relapse/refractory (RR), they reach multi-drug resistance (MDR) and stop responding to conventional chemotherapy and their multiple myeloma progresses without control.
Conventional oncology can’t cure multiple myeloma. MM patients should use every evidence-based therapy at their disposal. If you have been diagnosed with MM, job number one is to find and consult with a MM specialist.
To learn more about evidence-based, non-conventional therapies for MM, scroll down the page, post a question or comment and I will reply to you ASAP.
“Objectives-This study aimed to provide real‐world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death.
Methods- The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date.
Results- Data from 786 patients were reviewed. At the time of death:
Death before and during active first‐line treatment was not uncommon (6% and 24% of patients, respectively) but these deaths were often not solely due to disease progression; factors such as renal failure and infection frequently played a role (in 30% and 20% of patients at first‐line, respectively).
Most deaths at later lines were due to progressive disease. Cox model results suggested that early deaths were associated with:
Conclusions- These real‐world data could be used to help develop strategies for improving survival in patients with MM and to support management tailored to the stage of disease.”